Abstract
The introduction of nucleic acids into cells for therapeutic intervention is greatly impeded by the size and charge of these molecules and therefore requires sophisticated vectors that facilitate cellular uptake. Both viral and nonviral vectors have been developed for this purpose, each with their own advantages and shortcomings. The engineering of artificial viruses by dismantling virus particles or incorporating viral features into nonviral vectors represents a novel strategy to combine "the best of both worlds". © 2005 Elsevier Ltd. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 103-109 |
| Number of pages | 7 |
| Journal | Drug Discovery Today: Technologies |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 11 Jan 2005 |
Keywords
- 1,2 dioleoyl 3 trimethylammoniopropane
- epidermal growth factor receptor 2
- nucleic acid
- plasmid DNA
- polymer
- synthetic peptide
- viral protein
- virus vector
- article
- bioengineering
- breast cancer
- disease carrier
- DNA binding
- DNA packaging
- DNA vector
- drug uptake
- gene expression regulation
- gene targeting
- gene therapy
- gene transfer
- gene vector
- genetic engineering
- genetic transduction
- genetic transfection
- immunogenicity
- nanotechnology
- nonhuman
- nonviral gene delivery system
- nonviral gene therapy
- nuclear localization signal
- particle size
- receptor binding
- surface charge
- viral gene delivery system
- virus particle
